Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merrimack IPO nets $95.6mm

Executive Summary

Cancer drug developer Merrimack Pharmaceuticals Inc. has netted $95.6mm through its initial public offering by selling 14.3mm common shares at $7. The company originally filed in August 2011 and announced in January 2012 that it hoped to sell 16.67mm shares between $8-10 apiece. Shortly thereafter, there was speculation that Merrimack would postpone or withdraw its filing due to market conditions, but an accelerated S1 approval led the company to a successful pricing.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies